Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...
The trial confirmed linsitinib's favorable safety profile, with no QTc prolongation and manageable adverse events. Late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback